AudioAbstracts

A new analysis from the HEAR registry revealed that tafamidis is associated with significantly improved three-year survival in patients aged 80 and older with transthyretin cardiac amyloidosis (ATTR-CM). Hear from Dr. Hallie Blevins as she discusses this large real-world dataset and the importance of timely recognition and treatment of ATTR-CM in older patients—an often underrepresented group in clinical trials.

A new preclinical study investigated whether Roseburia hominis, a gut microbe often depleted in individuals with obesity, could play a direct role in regulating metabolism. Learn more as Dr. Hallie Blevins explores these findings and their potential implications for future treatment of obesity and related metabolic disorders in this AudioAbstract.

In older patients with unexplained hypertrophy, the default diagnosis of hypertrophic cardiomyopathy (HCM) may overlook a common culprit: transthyretin amyloid cardiomyopathy (ATTR-CM). In this AudioAbstract, Dr. Hallie Blevins explores the TTRACK study, which uncovered a striking prevalence of ATTR-CM in patients previously labeled with HCM and affirmed the real-world reliability of nuclear imaging in detecting it. Learn how imaging modalities, tracer choice, and subtle ECG or MRI findings can influence diagnostic accuracy and reshape our clinical approach.

Distinguishing psoriatic arthritis from erosive hand osteoarthritis isn’t always straightforward—but a new imaging approach may help. Tune in to hear Ryan Quigley discuss a recent study assessing fluorescence optical imaging (FOI) and its potential to improve diagnostic accuracy in this challenging clinical scenario.

Artificial intelligence is reshaping the landscape of psoriatic arthritis, offering new tools to improve diagnosis, risk assessment, and treatment response prediction. Hear Ryan Quigley discuss a narrative review that looked at emerging AI innovations in rheumatology and how they may enhance care for patients with psoriatic arthritis.

Elderly patients with both aortic stenosis and transthyretin cardiac amyloidosis face complex management decisions, but new data suggest that combining aortic valve replacement (AVR) with ATTR-specific therapy may significantly improve outcomes. In this AudioAbstract, Dr. Mimi Maeusli reviews a multinational study published in the European Heart Journal on the prognostic impact of targeted treatment in this dual-diagnosis population and explains how these findings may help guide more informed, individualized treatment strategies.

This is a non-certified educational series produced and controlled by ReachMD.

As CAR T-cell therapy becomes more widely used in multiple myeloma, understanding when toxicities occur is critical to balancing safety and access. Hear from Dr. Mimi Maeusli as she reviews new clinical and real-world findings on post-infusion monitoring for idecabtagene vicleucel (ide-cel) in patients with relapsed/refractory multiple myeloma (RRMM), which were presented at the International Myeloma Society Annual Meeting in September 2025.

Triple-negative breast cancer (TNBC) remains one of the hardest subtypes to treat, with limited options and high relapse rates—so identifying new therapeutic targets is critical. In this AudioAbstract, Ryan Quigley spotlights research presented at the San Antonio Breast Cancer Symposium that implicates ribosome biogenesis as a key vulnerability. Tune in to learn how this approach could inform the next generation of TNBC therapies.

How are patients with breast cancer brain metastases faring in the modern treatment era? In this AudioAbstract, Ryan Quigley shares findings from a 25-year review of 507 patients at UCSF, providing new insights into how survival outcomes have shifted across subtypes and which treatments are driving real-world progress. This research was also presented at the 2025 San Antonio Breast Cancer Symposium.

At the 2025 American Society of Hematology Annual Meeting and Exposition, researchers presented key findings from the pivotal phase three CLL17 trial, which was the first randomized study to directly compare continuous BTK inhibition with fixed-duration venetoclax-based therapy in previously untreated chronic lymphocytic leukemia (CLL). Hear from Ryan Quigley as he shares new data on efficacy and safety and their potential long-term implications for patients with CLL in this AudioAbstract.